Results 71 to 80 of about 7,978,447 (307)

Treatment effect estimates for major adverse cardiovascular events (MACE).

open access: yes, 2019
Treatment effect estimates for major adverse cardiovascular events (MACE).
Théodora Bejan-Angoulvant (2147893)   +15 more
core   +1 more source

The Gut–Heart Axis in Systemic Sclerosis: Evidence From a Large Prospective Early Disease Cohort

open access: yesArthritis Care &Research, EarlyView.
Objective Cardiac involvement significantly impacts prognosis in systemic sclerosis (SSc), highlighting the need for early risk stratification. Gastrointestinal (GI) symptoms are common and often manifest early. Emerging data suggest a link between GI and cardiac manifestations, possibly through shared mechanisms like dysautonomia.
Francesca R. Di Ciommo   +9 more
wiley   +1 more source

Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6

open access: yesCardiovascular Diabetology, 2022
Background Cardiovascular outcome trials (CVOTs) are conducted on a background of standard of care including metformin. These analyses sought to determine whether the cardiovascular (CV) effects of semaglutide and other glucagon-like peptide-1 receptor ...
Mansoor Husain   +5 more
doaj   +1 more source

Perioperative Major Adverse Cardiovascular and Cerebrovascular Events Associated With Noncardiac Surgery [PDF]

open access: yesJAMA Cardiology, 2017
Major adverse cardiovascular and cerebrovascular events (MACCE) are a significant source of perioperative morbidity and mortality following noncardiac surgery.To evaluate national trends in perioperative cardiovascular outcomes and mortality after major noncardiac surgery and to identify surgical subtypes associated with cardiovascular events using a ...
Nathaniel R, Smilowitz   +5 more
openaire   +2 more sources

Kaplan–Meier plots, with 95% confidence intervals, for time to first major adverse cardiovascular event by diabetes cohort and baseline eGFR category.

open access: yes, 2019
a. Type 1 diabetes, b. Type 2 diabetes, c. Non-diabetes, d. Overall MACE, major adverse cardiovascular event. eGFR, estimated glomerular filtration rate.
Thomas R. Berni (7321634)   +7 more
core   +1 more source

Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study From the EUSTAR Cohort

open access: yesArthritis Care &Research, EarlyView.
Objective JAK inhibitors (JAKi) have shown promising effects in early‐phase studies of systemic sclerosis (SSc). We aimed to assess the safety and explore the effectiveness of JAKi compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the European Scleroderma Trials and Research Group (EUSTAR) cohort was ...
Stefano Di Donato   +27 more
wiley   +1 more source

An Aggregate Biomarker Risk Score Predicts High Risk of Near‐Term Myocardial Infarction and Death: Findings From BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes)

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
BackgroundIn a previous study, we found that a biomarker risk score (BRS) comprised of C‐reactive protein, fibrin‐degradation products, and heat shock protein‐70 predicts risk of myocardial infarction and death in coronary artery disease patients.
Nima Ghasemzadeh   +7 more
doaj   +1 more source

Kaplan–Meier curves for stroke/SEE, all bleeding, major bleeding, intracranial hemorrhage, all-cause death, and major adverse cardiovascular or neurological event.

open access: yes, 2023
Abbreviations: PAF, paroxysmal atrial fibrillation; SEE, systemic embolic events; MACNE, major adverse cardiovascular or neurological events.
Takenori Yamaguchi (9606963)   +17 more
core   +1 more source

Clinician and Patient Factors Associated With Long‐Term Glucocorticoid Use in People With Rheumatoid Arthritis Receiving Advanced Therapies

open access: yesArthritis Care &Research, EarlyView.
Objective Despite guideline recommendations, long‐term glucocorticoid (GC) use is common in rheumatoid arthritis (RA). We conducted a clinician survey nested within a large registry to identify patient and clinician factors associated with GC use. Methods Clinicians contributing patients to the CorEvitas Rheumatoid Arthritis Registry were surveyed ...
Michael D. George   +7 more
wiley   +1 more source

Exploring prognostic factors on vascular outcomes among maintenance dialysis patients and establishing a prognosis prediction model using machine learning methods

open access: yesBMC Medical Informatics and Decision Making
Background Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality in end-stage kidney disease patients, with persistently high rates of major adverse cardiovascular events (MACEs). Traditional risk factors such as diabetes and
Chung-Kuan Wu   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy